Lucinactant
Tóm tắt
▲ Lucinactant, formerly known as KL4 surfactant, is a novel synthetic lung surfactant containing phospholipids and an engineered peptide, sinapultide, which is designed to mimic the actions of human surfactant protein B. It has been developed for use in the prevention or treatment of respiratory distress syndrome (RDS), a common problem in premature infants, which results from a deficiency or degradation of pulmonary surfactant. Lucinactant is administered intratracheally soon after birth as a replacement surfactant. ▲ In the pivotal randomized, double-blind, prophylaxis trial in premature infants, the incidence of RDS at 24 hours after birth was significantly lower in lucinactant recipients than in recipients of colfosceril palmitate, a synthetic non-protein-containing surfactant. RDS-related mortality at 14 days was significantly lower in lucinactant recipients than in recipients of colfosceril palmitate or beractant, a bovine-derived surfactant. ▲ In another randomized, double-blind, prophylaxis trial in premature infants, the rate of survival without bronchopulmonary dysplasia at 28 days of age in lucinactant recipients was not inferior to that in recipients of poractant alfa, a porcine-derived surfactant. ▲ Lucinactant was generally well tolerated. Adverse events were transient and related to the administration procedure. There were no differences in the incidences of complications of prematurity between lucinactant and the other surfactants.
Tài liệu tham khảo
Boyd S. Causes and treatment of neonatal respiratory distress syndrome. Nurs Times 2004 Jul; 100(30): 40–4
Lewis JF. Surfactant: where are we in 2003? Can Respir J 2004; 11(3): 204–6
Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents? Pediatric Drugs 2002; 4(No. 8): 485–92
Ainsworth SB, Milligan DWA. Surfactant therapy for respiratory distress syndrome in premature neonates: A comparative review. Am J Respir Med 2002; 1(6): 417–33
Data on file. Discovery Laboratories, 2005
Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991 Oct 25; 254(5031): 566–8
Notter RH, Wang Z, Egan EA, et al. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002 Jan; 114(1): 21–34
Physicians’ Desk Reference. Montvale (NJ): Thomson PDR, 2005
Doyle I. Lucinactant (Discovery Laboratories). Idrugs 2002 Jul; 5(7): 696–702
Cruz A, Vazquez L, Velez M, et al. Effect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipid films. Biophys J 2004 Jan; 86(1): 308–20
Cochrane CG, Revak SD. Protein-phospholipid interactions in pulmonary surfactant. Chest 1994 Mar; 105Suppl. 3: 57S–62S
Gustafsson M, Vandenbussche G, Curstedt T, et al. The 21-residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane α-helix with a mixed nonpolar/polar surface. FEBS Lett 1996 Apr 15; 384(2): 185–8
Ma J, Koppenol S, Yu H, et al. Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers. Biophys J 1998 Apr; 74(4): 1899–907
Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996 Apr; 39 (4 Pt 1): 715–24
Nutt M, Patel N, Rairkar M, et al. Comparison of the novel lung surfactant surfaxin® (lucinactant) with currently available commercial products [abstract no. 2912]. Pediatric Academic Societies’ Annual Meeting; 2004 May 1–4; San Francisco
Merritt TA, Amirkhanian JD, Helbock H, et al. Reduction of the surface-tensionlowering ability of surfactant after exposure to hypochlorous acid. Biochem J 1993 Oct 1; 295: 19–22
Manalo E, Merritt TA, Kheiter A, et al. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr Res 1996 Jun; 39(6): 947–52
Sood SL, Balaraman V, Finn KC, et al. Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1996 Feb; 153: 820–8
Merritt TA, Kheiter A, Cochrane CG. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 1995 Aug; 38(2): 211–7
Moya F, Gadzinowski J, Bancalari E, et al. A multicenter randomized masked comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome in very preterm infants. Pediatrics (In press)
Sinha S, Lacaze-Masmonteil T, Valls i Soler A, et al. A randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress sydrome. Pediatrics (In press)
Discovery Laboratories [online]. Available from URL: http://www.discoverylabs.com
Cochrane CG, Revak SD, Merritt A, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996 Jan; 153: 404–10
Suresh GK, Soll RF. Current surfactant use in premature infants. Clin Perinatol 2001 Sep; 28(3): 671–94